Physician profile
Bryan A Selkin
NPI 1679543847
$12,526.99
in general payments reported to CMS, 2019-2025
43 companies · $3,053 in 2025
The $3,053 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,659 · 2020: $1,037 · 2021: $704 · 2022: $1,013 · 2023: $2,305 · 2024: $2,755 · 2025: $3,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,094 · Education: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,093.66 |
| Education | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,219.41 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $1,228.24 | 2019-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $1,083.39 | 2023-2025 | Zoryve |
| Amgen INC. | $696.19 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $674.64 | 2020-2025 | Nemluvio, Aklief, Epsolay |
| Sun Pharmaceutical Industries INC. | $667.89 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Dermavant Sciences, INC. | $656.17 | 2022-2024 | Vtama |
| Genzyme Corporation | $627.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $471.08 | 2019-2025 | |
| Leo Pharma INC. | $308.36 | 2020-2025 | Adbry, Anzupgo |
| Misonix INC | $303.64 | 2020-2021 | |
| Pfizer INC. | $266.92 | 2019-2025 | |
| Allergan, INC. | $262.12 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $252.82 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $239.37 | 2019-2024 | Tremfya |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $205.08 | 2023-2025 | Xtrac |
| Lilly USA, LLC | $185.32 | 2019-2023 | Taltz, Olumiant |
| Dermira, INC. | $145.85 | 2019-2021 | |
| Ucb, INC. | $133.19 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $99.79 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $86.72 | 2020-2021 | |
| Botanix Sb INC | $81.89 | 2025 | Sofdra |
| Incyte Corporation | $74.40 | 2023-2025 | Opzelura |
| Elekta, INC. | $55.63 | 2023 | Elekta Medical Linear Accelerator |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.91 | 2022-2023 | Spevigo |
| Genentech USA, INC. | $51.75 | 2019-2022 | |
| Dusa Pharmaceuticals, INC. | $39.60 | 2019 | |
| Encore Dermatology INC. | $34.32 | 2019 | |
| Revance Therapeutics, INC. | $32.99 | 2025 | Daxxify |
| Kerecis Limited | $31.80 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Almirall LLC | $29.61 | 2019-2023 | Seysara |
| Sientra, INC. | $27.71 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.97 | 2020 | |
| Cipher Pharmaceuticals US LLC | $23.53 | 2025 | Spinosad, Natroba |
| Organogenesis INC. | $20.66 | 2023 | Puraply |
| Biofrontera INC. | $20.01 | 2019 | |
| Epi Health, LLC | $18.27 | 2019 | |
| Organon LLC | $17.40 | 2025 | Vtama |
| Novum Pharma, LLC | $17.26 | 2019 | |
| Mayne Pharma Commercial LLC | $16.66 | 2021 | |
| Aclaris Therapeutics, INC. | $14.91 | 2019 | |
| Celgene Corporation | $14.68 | 2019 | |
| Allegis Pharmaceuticals, LLC | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Selkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.